We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $5.34B
1-Year Est. Return 380.18%
This Fund
S&P 500
This Quarter Est. Return
+19.93%
1 Year Est. Return
+380.18%
3 Year Est. Return
+803.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.29B
AUM Growth
+$239M
Cap. Flow
+$115M
Cap. Flow %
8.87%
Top 10 Hldgs %
54.55%
Holding
35
New
10
Increased
17
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$60.8M
2
NUVL
Nuvalent
NUVL
+$42.4M
3
VIR icon
Vir Biotechnology
VIR
+$25.5M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$23M
5
ACLX
Arcellx
ACLX
+$22.5M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$97.2M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$57.1M
3
KROS icon
Keros Therapeutics
KROS
+$39.7M
4
ASND icon
Ascendis Pharma A/S
ASND
+$37.6M
5
ARGX icon
argenx
ARGX
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.48%
2 Miscellaneous 4.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
1
Legend Biotech
LEGN
$3.42B
$125M 9.63%
1,805,717
+295,393
+20% +$19.3M
INCY icon
2
Incyte
INCY
$25.9B
$86M 6.65%
1,381,711
+120,000
+10% +$8.02M
IMCR icon
3
Immunocore
IMCR
$1.66B
$76.2M 5.88%
1,270,124
+143,868
+13% +$8.21M
ACLX
4
DELISTED
Arcellx
ACLX
$74.2M 5.73%
2,347,000
+589,221
+34% +$22.5M
KRTX
5
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$61.5M 4.75%
+283,605
New +$60.8M
CERE
6
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$59.4M 4.59%
1,868,946
+273,747
+17% +$8.4M
ARGX icon
7
PUT
argenx
ARGX
$62.3B
$58.5M 4.52%
+150,000
New +$59M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.48B
$57.5M 4.44%
2,415,256
+329,558
+16% +$8.45M
ARGX icon
9
argenx
ARGX
$62.3B
$55.4M 4.28%
142,259
-38,913
-21% -$15.3M
UTHR icon
10
United Therapeutics
UTHR
$21.3B
$52.6M 4.07%
238,388
+26,496
+13% +$5.87M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$52.2M 4.03%
1,443,762
+46,983
+3% +$1.94M
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.58B
$50.7M 3.92%
2,424,132
+149,620
+7% +$3.12M
BCYC
13
Bicycle Therapeutics
BCYC
$258M
$50.7M 3.92%
1,985,430
+168,649
+9% +$3.92M
NUVL
14
DELISTED
Nuvalent
NUVL
$47.3M 3.65%
+1,120,465
New +$42.4M
ONC
15
BeOne Medicines Ltd
ONC
$40B
$38.5M 2.98%
216,093
+32,081
+17% +$7.39M
XENE icon
16
Xenon Pharmaceuticals
XENE
$5.55B
$38.1M 2.94%
989,327
+338,259
+52% +$13.4M
OLMA icon
17
Olema Pharmaceuticals
OLMA
$866M
$33.7M 2.6%
3,731,046
+1,348,669
+57% +$8.14M
AMAM
18
DELISTED
Ambrx Biopharma Inc
AMAM
$27.2M 2.1%
+1,650,499
New +$20.8M
CRNX
19
DELISTED
Crinetics Pharmaceuticals
CRNX
$25.1M 1.94%
1,395,002
+261,220
+23% +$5.21M
ALPN
20
DELISTED
Alpine Immune Sciences Inc
ALPN
$24.9M 1.93%
2,423,961
+106,327
+5% +$959K
VIR icon
21
Vir Biotechnology
VIR
$1.85B
$24.9M 1.92%
+1,014,239
New +$25.5M
ZLAB icon
22
Zai Lab
ZLAB
$2.9B
$24M 1.85%
865,297
+84,739
+11% +$2.77M
IMTX icon
23
Immatics
IMTX
$1.34B
$22.9M 1.77%
+1,984,813
New +$18.5M
AUTL
24
Autolus Therapeutics
AUTL
$511M
$21.9M 1.7%
+9,217,150
New +$21.9M
VOR icon
25
Vor Biopharma
VOR
$1.3B
$20M 1.54%
323,073
-827
-0.3% -$75.5K
1
2

Similar funds

FFB
First Financial Bankshares Abilene, Texas $5.34B AUM 28.75% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
CAU
Caxton Associates (UK) London $5.33B AUM 59.38% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $5.32B AUM 22.63% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return
Twin Tree Management
Twin Tree Management Dallas, Texas $5.31B AUM 55.82% 1-Year Est. Return

Paradigm Biocapital Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Paradigm Biocapital Advisors held 35 positions worth $1.29B, up 23% from $1.06B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Paradigm Biocapital Advisors deployed $115M of net new capital in Q2 2023, opening 10 new positions and adding to 17 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 283,605 shares worth $61.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was argenx, an estimated $15.3M trimmed.

  • Paradigm Biocapital Advisors's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 283,605 shares worth $61.5M.
  • Paradigm Biocapital Advisors added most to Arcellx in Q2 2023, an estimated $22.5M increase.
  • Paradigm Biocapital Advisors's biggest Q2 2023 reduction was argenx, cutting an estimated $15.3M.
  • Paradigm Biocapital Advisors fully exited Biogen in Q2 2023, selling an estimated $97.2M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 55% of its $1.29B portfolio in Q2 2023.
  • Paradigm Biocapital Advisors opened 10 new positions and closed 5 in Q2 2023.
  • Paradigm Biocapital Advisors's portfolio value rose 23% quarter-over-quarter to $1.29B.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.